Compare FICO & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | TEVA |
|---|---|---|
| Founded | 1956 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7B | 33.5B |
| IPO Year | 1995 | N/A |
| Metric | FICO | TEVA |
|---|---|---|
| Price | $923.69 | $30.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $1,848.17 | $38.63 |
| AVG Volume (30 Days) | 328.9K | ★ 5.6M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.78 | N/A |
| EPS | ★ 6.61 | N/A |
| Revenue | ★ $1,032,475,000.00 | N/A |
| Revenue This Year | $27.28 | N/A |
| Revenue Next Year | $17.01 | $3.24 |
| P/E Ratio | $162.08 | ★ $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $969.32 | $13.04 |
| 52 Week High | $2,217.60 | $37.35 |
| Indicator | FICO | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 28.68 | 52.79 |
| Support Level | N/A | $30.70 |
| Resistance Level | $1,829.71 | $31.99 |
| Average True Range (ATR) | 55.88 | 0.95 |
| MACD | 3.95 | 0.31 |
| Stochastic Oscillator | 6.09 | 82.51 |
Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.